Market Cap 490.36M
Revenue (ttm) 23.61M
Net Income (ttm) -105.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -446.89%
Debt to Equity Ratio 0.46
Volume 663,900
Avg Vol 1,674,074
Day's Range N/A - N/A
Shares Out 56.30M
Stochastic %K 87%
Beta 1.01
Analysts Strong Sell
Price Target $22.86

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology
Sector: Healthcare
Phone: 321 939 3416
Website: zevra.com
Address:
1180 Celebration Boulevard, Suite 103, Celebration, United States
peugout505
peugout505 Dec. 7 at 11:39 PM
$AQST $ZVRA Aging well. 🚀
0 · Reply
KemPharm_rocks
KemPharm_rocks Dec. 7 at 11:38 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 9:24 PM
Enter: $ZVRA Calls Strike Price: $9 Expiry Date: JAN 16 2026 Buy in Price: $0.85 - $1.05 Sell Price: $1.30 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 6 at 1:26 AM
Enter: $ZVRA Calls Strike Price: $9 Expiry Date: JAN 16 2026 Buy in Price: $0.82 - $0.90 Sell Price: $1.43 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
KemPharm_rocks
KemPharm_rocks Dec. 6 at 1:22 AM
0 · Reply
wk2srt17
wk2srt17 Dec. 5 at 10:59 PM
$ZVRA just know this stock is like a girlfriend that keeps cheating on you and you know it and you take her back anyways again and again and again. Chiefdiddy you are use to it though. 😂
1 · Reply
HuntingHighAndLow
HuntingHighAndLow Dec. 5 at 9:43 PM
$ZVRA He sold and bought a boat.
0 · Reply
ChiefTanto
ChiefTanto Dec. 5 at 9:04 PM
$ZVRA Less than half 30d avg vol. Odd.
2 · Reply
BigGainTom
BigGainTom Dec. 5 at 6:47 PM
$ZVRA Did Rod sell?
0 · Reply
RaySan
RaySan Dec. 5 at 6:29 PM
$ZVRA Very low volume today. Why?
1 · Reply
Latest News on ZVRA
Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 17 days ago

Zevra Therapeutics, Inc. Announces CFO Transition


Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 8:43 PM EDT - 4 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript


Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:45 PM EDT - 7 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript


Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 8 months ago

Zevra Therapeutics Files Preliminary Proxy


Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:16 PM EDT - 9 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript


Zevra to Participate at Upcoming Investor Conferences

Feb 24, 2025, 4:02 PM EST - 10 months ago

Zevra to Participate at Upcoming Investor Conferences


Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 30, 2025, 7:30 AM EST - 11 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™


Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 29, 2025, 4:05 PM EST - 11 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences


Zevra Therapeutics Announces Organizational Changes

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes


US FDA approves Zevra's genetic disorder treatment

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment


peugout505
peugout505 Dec. 7 at 11:39 PM
$AQST $ZVRA Aging well. 🚀
0 · Reply
KemPharm_rocks
KemPharm_rocks Dec. 7 at 11:38 PM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 7 at 9:24 PM
Enter: $ZVRA Calls Strike Price: $9 Expiry Date: JAN 16 2026 Buy in Price: $0.85 - $1.05 Sell Price: $1.30 Profit : +53% (Turn every $1 into $1.53) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 6 at 1:26 AM
Enter: $ZVRA Calls Strike Price: $9 Expiry Date: JAN 16 2026 Buy in Price: $0.82 - $0.90 Sell Price: $1.43 Profit : +74% (Turn every $1 into $1.74) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
KemPharm_rocks
KemPharm_rocks Dec. 6 at 1:22 AM
0 · Reply
wk2srt17
wk2srt17 Dec. 5 at 10:59 PM
$ZVRA just know this stock is like a girlfriend that keeps cheating on you and you know it and you take her back anyways again and again and again. Chiefdiddy you are use to it though. 😂
1 · Reply
HuntingHighAndLow
HuntingHighAndLow Dec. 5 at 9:43 PM
$ZVRA He sold and bought a boat.
0 · Reply
ChiefTanto
ChiefTanto Dec. 5 at 9:04 PM
$ZVRA Less than half 30d avg vol. Odd.
2 · Reply
BigGainTom
BigGainTom Dec. 5 at 6:47 PM
$ZVRA Did Rod sell?
0 · Reply
RaySan
RaySan Dec. 5 at 6:29 PM
$ZVRA Very low volume today. Why?
1 · Reply
intowits
intowits Dec. 5 at 4:47 PM
$ZVRA "Celiprolol Therapy Celiprolol (a beta-blocker with vasodilatory properties) should be initiated to reduce vascular morbidity, based on two retrospective studies and one randomized open-label trial showing three-fold reduction in arterial rupture. 1,3 Starting celiprolol after 10 years of age is considered reasonable by expert consensus, though no definitive age recommendation exists. 1 Note that celiprolol lacks FDA approval in the United States but is recommended by European guidelines." https://www.droracle.ai/articles/570623/what-is-the-management-plan-for-vascular-ehlers-danlos-syndrome
0 · Reply
intowits
intowits Dec. 5 at 4:37 PM
$ZVRA 20 days until the flyout!
0 · Reply
DevAd
DevAd Dec. 5 at 3:36 PM
0 · Reply
wk2srt17
wk2srt17 Dec. 5 at 3:33 PM
$ZVRA ZBI is at $123 today  and the zebras at $8.32 I thought they correlated one’s going up and one’s going down.
1 · Reply
OldManLogan
OldManLogan Dec. 5 at 3:22 PM
$ZVRA 1) Fire Neil. 2) Replace with an exec that knows how to negotiate a sale and how to maximize a company's assets. 3) Do whatever it takes to accelerate Celiprolol trial or halt it early to leverage the new rare disease approval pathway that was created. Leverage KP1077, most people forgot it existed. 5) Freaking fix Olpruva, it's the best formulation in its drug class, embarassing that it isn't outselling peers. 6) Get EU approval for Miplyffa. 7) Get max patent term extension in the US. 8) Do something productive with your cash. You do all this, stock probably gets to $20 naturally and then we could all sit around talking about a BO in the $30S or $40S... but none of this happens unless you fix #1 first.
2 · Reply
intowits
intowits Dec. 5 at 2:47 PM
$ZVRA "Stonepine Capital boosted its shares of Zevra by 19.3% in the 2nd qtr. They owned 775,620 shares of Zevra's stock after buying an additional 125,620 shares. Zevra accounts for about 6.7% of Stonepine Capital's investment portfolio, making the stock its 3rd biggest holding. Stonepine Capital owned 1.42% of Zevra worth $6,833,000. Quantbot Technologies bought Zevra shrs in the 2nd qtr valued at about $255,000. Schroder Investment purchased Zevra shrs in the 2nd qtr worth $ 2,779,000. Ameritas Investment grew its position in shares of Zevra by 30.0% in the 2nd qtr. Rhumbline Advisers raised its stake in Zevra by 11.6% in the 2nd qtr. Rhumbline now owns 83,221 shares of the Zevra's stock worth $733,000 after acquiring an 8,636 shares in the last qtr. Finally, Legal & General Group lifted its position in Zevra by 26.8% in the 2nd qtr. Legal & General now owns 935,677 shares of Zevra's stock valued at $ 8,243,000 after acquiring an additional 197,940 shrs during the last qtr."
0 · Reply
wk2srt17
wk2srt17 Dec. 5 at 2:46 PM
$ZVRA buyout? Are we talking about buyout? Buyout? Nobody wants to buy this company of 14 employees which 98% of them do nothing!
3 · Reply
intowits
intowits Dec. 5 at 2:17 PM
0 · Reply
BMW2002
BMW2002 Dec. 5 at 12:03 PM
0 · Reply
sarandonguero
sarandonguero Dec. 5 at 11:39 AM
$ZVRA What is your price forecast for BO??? I SAY $54
jemer
jemer Dec. 4 at 10:44 PM
$ZVRA i am predicting a Buyout for $16 in February with a $4.X CRV for European approval for Miplyffa and $2.X CRV for Miplyffa PTE extension to Sept 2034. Feels about right to me.
9 · Reply
Leeststorm
Leeststorm Dec. 4 at 8:46 PM
$ZVRA just sell the damn company and move on please - do something to benefit shareholders for a change
0 · Reply